학술논문
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Document Type
Article
Author
Kumar, Shaji K ; Jacobus, Susanna J; Cohen, Adam D; Weiss, Matthias; Callander, Natalie; Singh, Avina K; Parker, Terri L; Menter, Alexander; Yang, Xuezhong; Parsons, Benjamin; Kumar, Pankaj; Kapoor, Prashant; Rosenberg, Aaron; Zonder, Jeffrey A; Faber, Edward, Jr; Lonial, Sagar; Anderson, Kenneth C; Richardson, Paul G; Orlowski, Robert Z; Wagner, Lynne I; Rajkumar, S Vincent
Source
In The Lancet Oncology October 2020 21(10):1317-1330
Subject
Language
ISSN
1470-2045